The EUGeneHeart Integrated Project will develop new strategies to inhibit detrimental and promote beneficial hypertrophic signalling. This includes translational research on existing pharmacological interventions, proof of principle studies with molecules, already developed by the consortium as well as the development of new candidate molecules identified within the project. Significant gender differences in physiology and pathophysiology of adaptive and maladaptive myocardial hypertrophy will be investigated, expertise or at least the willingness to explore this field is mandatory. The SME is expected to produce therapy targets curing hypertrophy and/or treat heart failure, develop potential drug targets, provide targets (newly generated molecules or molecules already available to the SME, specifically modulating the activity of cardiomyocyte signalling) to be tested by the consortium.

Favoured research experience:
1. Technology and /or know-how on drug discovery, experience in drug delivery
2. Ability to design and produce specific molecules
3. Access to small molecule libraries
4. Having small molecule screening platforms available
5. Access to automation technology would be a plus
6. Access to drug testing platforms would be an advantage
7. Provision of knowledge or technology to the consortium, based on promising candidate targets, candidate drugs, or therapeutic strategies, as well as strategies likely to increase the chances for development of a candidate drug based on the findings gained from EUGeneHeart Work Packages or knowledge from outside the consortium.

Expected duration of participation in project: from July 2007 to December 2010; Budget available: € 240.000
Please, note that only paper submission is possible for this call.

For more details please, follow the link read more